Kritsiriwuthinan Kanyanan, Wajanarogana Sumet, Choosang Kantima, Homsian Jetsada, Rerkthanom Sukritta
Faculty of Medical Technology, Rangsit University, MuangAke, Pathumthani, 12000, Thailand.
Department of Basic Medical Science, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, 10300, Thailand.
Acta Trop. 2018 Feb;178:333-339. doi: 10.1016/j.actatropica.2017.10.019. Epub 2017 Oct 23.
Melioidosis is a bacterial infectious disease caused by Burkholderia pseudomallei (B. pseudomallei). The variable clinical manifestations of this disease make its diagnosis difficult. The gold standard strategy for diagnosis is bacterial culture and identification, which is time-consuming and often too late for early medical intervention. Therefore, a rapid and accurate diagnosis of melioidosis is needed for effective treatment. This study aimed to produce and evaluate two purified B. pseudomallei recombinant proteins (rGroEL and rOmpA) as potential antigens for melioidosis diagnosis by ELISA. A total of 218 serum samples from Thailand was analysed. The study includes melioidosis patients' serum samples confirmed by bacterial culture (n=38); sera from patients with various bacterial infections but negative for B. pseudomallei (disease control, n=55); and sera from healthy individuals from non-endemic (n=77) and endemic (n=48) regions. The rGroEL ELISA achieved a good sensitivity of 92%, which was higher than that of rOmpA ELISA (76%). The specificities of rGroEL and rOmpA ELISAs were 88% and 90%, respectively. Both antigens demonstrated good diagnostic accuracy, at 89% (rGroEL) and 88% (rOmpA). There was less reactivity of sera from healthy individuals with rGroEL than rOmpA antigens. These data highlight the usefulness of rGroEL purified protein as a potential antigen for the serodiagnosis of melioidosis by ELISA and may be useful in the development of additional methods, such as dot blot ELISA or immunochromatographic tests (ICT), for a rapid, simple, cost-effective and efficient diagnosis for use in poorly resourced regions where melioidosis is endemic.
类鼻疽是由类鼻疽伯克霍尔德菌引起的一种细菌性传染病。该疾病临床表现多样,诊断困难。诊断的金标准方法是细菌培养和鉴定,但这耗时较长,且往往错过早期医疗干预的时机。因此,为了进行有效治疗,需要快速准确地诊断类鼻疽。本研究旨在制备并评估两种纯化的类鼻疽伯克霍尔德菌重组蛋白(rGroEL和rOmpA),作为通过酶联免疫吸附测定(ELISA)诊断类鼻疽的潜在抗原。共分析了来自泰国的218份血清样本。该研究包括经细菌培养确诊的类鼻疽患者血清样本(n = 38);患有各种细菌感染但类鼻疽伯克霍尔德菌检测呈阴性的患者血清(疾病对照,n = 55);以及来自非流行地区(n = 77)和流行地区(n = 48)的健康个体血清。rGroEL ELISA的灵敏度达92%,表现良好,高于rOmpA ELISA(76%)。rGroEL和rOmpA ELISA的特异性分别为88%和90%。两种抗原的诊断准确率均较高,分别为89%(rGroEL)和88%(rOmpA)。与rOmpA抗原相比,健康个体血清与rGroEL的反应性较低。这些数据突出了rGroEL纯化蛋白作为ELISA血清学诊断类鼻疽潜在抗原的有用性,并且可能有助于开发其他方法,如斑点印迹ELISA或免疫层析试验(ICT),以用于类鼻疽流行的资源匮乏地区进行快速、简单、经济高效的诊断。